Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance

An early molecular response is spectacularly predictive of outcome in chronic myeloid leukemia (CML) and early response landmarks may identify the high-risk patients likely to be benefit from an early therapy switch. In this study, we evaluated the most relevant cutoffs for early molecular response...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jingru, Wang, Yingqiao, Wang, Jianxiang, Hu, Jianda, Chen, Suning, Jin, Jie, Liu, Ting, Zhou, Jianfeng, Hu, Yu, Ma, Daoxin, Huang, Xiaojun, Ji, Chunyan, Hou, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006175/
https://www.ncbi.nlm.nih.gov/pubmed/29915172
http://dx.doi.org/10.1038/s41408-018-0093-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006175/
https://www.ncbi.nlm.nih.gov/pubmed/29915172
http://dx.doi.org/10.1038/s41408-018-0093-4

Ejemplares similares